Eric Cheung, DO, Targeted Oncology’s second 2024 Oncology Icon, discussed his journey in oncology, advances in treatment, and ...

Researchers have identified the genetic risk factors that contribute to prostate cancer in a diverse group of African men.

Company also reports positive data from trial of combination treatment for a form of prostate cancer Pfizer Inc.'s stock dipped 2.5% Thursday after two of its former executives said they would not ...

Former Portsmouth goalkeeper Alan Knight has revealed he has advanced prostate cancer. The 61-year spent 22 years at Fratton Park, making 801 appearances between 1978 and 2000 – the record for a ...

This new centre focuses on treating benign prostatic hyperplasia (BPH) using advanced, patient-centred technology, including ...

The survival rate of men with prostate cancer who had their entire prostate gland removed immediately after the tumor was ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

The overall survival data from the late-stage trial will help Pfizer in its bid to expand the label for Talzenna and Xtandi, ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...

In prostate cancer, Pfizer’s Talzenna already holds the broadest FDA approval within the PARP inhibitor class. | In prostate ...